
Emphasis
The emphasis is on engineering of targeting and responsive molecular probes of high sensitivity and specificity for PET and SPECT (radiotracers), MR (T1, T2, CEST, hyperpolarized agents), EPR, CT, optical (fluorescent and bioluminescent probes), ultrasound (microbubbles) and photoacoustic imaging. The imaging agents may be based on nano- and micro-particles, liposomes, dendrimers, proteins, small organic and inorganic molecules etc., and detectable by one or more imaging modalities. Imaging agent development through methodologies such as chemical synthesis, biological mutagenesis, microfabrication, etc., may be pursued with an intent of leading to in vivo biomedical application.
Outcome
The goal of this program is to generate robust molecular probes, imaging agents and platforms for biomedical application across all disease areas to facilitate diagnostics and improve understanding of disease state, progression, and therapeutic response.
Additional emphasis
This program also supports the development of other imaging agents, for example:
- multimodal molecular probes (PET/MRI, PET/fluorescent, etc.)
- imaging reporter genes and reporter gene/imaging probe duos
- molecular probes as part of theranostic systems or biosensors
- imaging agents for cell labelling and in vivo tracking
- molecular probes for image-guided interventions
Note
The following related scientific areas are supported by other NIBIB programs:
- development of biomaterials is supported by the Biomaterials and Biomolecular Constructs program
- synthetic biology approaches are supported by the Synthetic Biology for Technology Development program
- development of associated imaging methods and related hardware/software is supported by NIBIB programs for specific imaging modalities
- image processing technology is supported by the Image Processing, Visualization, Perception and Display
Related News
Many cancer drugs fail to penetrate deep into tumors, but new research suggests magnetism could help pull them through.
The National Institutes of Health (NIH) has selected four finalists with innovative, non-invasive technologies that seek to improve diagnosis of endometriosis.
In a preclinical study, NIBIB researchers found that bone marrow transplants to treat sickle cell disease early in life may lower risk of stroke into adulthood.
The low image quality of small, affordable MRI machines have prevented their widespread use. But a boost from AI could close the gap, bringing MRI to more patients.
NIH has awarded more than $4 million in funds and support services to three diagnostic technology developers as part of RADx ® Tech’s Advanced Platforms for HIV Viral Load Monitoring program.